Gregory LizéeDepartment of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA F1000 Associate Faculty Member (since 23 November 2009)
Gregory Lizée is an Associate Faculty Member who works with Faculty Member Wilfred Jefferies to recommend the scientific literature in their field.ACADEMIC POSITION:
Assistant Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2000 University of British Columbia, Vancouver, BC, Canada, PhD, Immunology
1991 Simon Fraser University, Burnaby, BC, Canada, BS, Biological Sciences
11/2001-11/2003 Research Fellowship, Tumor Immunology, Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, Dr Steven A Rosenberg
5/2000-10/2001 Research Fellowship, Immunology, Biomedical Research Center, Vancouver, BC, Canada, Dr Wilfred A Jeffries
1995-1999 British Columbia Science Council Industrial Liaison Scholarship, University of British Columbia, Vancouver
My research focuses on two distinct aspects of tumor immunology. The first involves characterizing regulatory immune cells and mechanisms that are predominant in melanoma tumors and draining lymph node microenvironments at various stages of disease. These studies will aim to identify the types of immune regulation that are most important in melanoma with an eye toward attenuating or eliminating these mechanisms in future clinical endeavors. We are also examining the potential immunoregulatory function of BRAF kinase, which is somatically mutated in approximately two-thirds of human melanomas.
My laboratory is also studying the process of tumor antigen cross-presentation by dendritic cells (DCs). Specifically, we are examining the role of the MHC class I cytoplasmic domain in controlling intracellular trafficking and DC cross-presentation in the context of different immunological danger signals (for example, TLR ligands, interferons, and CD40L). This project has both basic and applied aspects in that gaining a better understanding of DC cross-presentation will not only help shed light on unknown aspects of DC biology but also hopefully provide useful concepts on which to base the next generation of DC-based cancer vaccines.
Gregory Lizée has been added to your "Faculty I'm Following" page in MyF1000
Follow/Unfollow any Faculty via their recommendations, biography pages, or MyF1000